A multicenter, randomized, double-blind, placebo-controlled efficacy study comparing 4 weeks of treatment with esomeprazole 20 mg qd to placebo qd in patients with heartburn and sleep disturbances associated with gastroesophageal reflux disease (GERD)

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled efficacy study comparing 4 weeks of treatment with esomeprazole 20 mg qd to placebo qd in patients with heartburn and sleep disturbances associated with gastroesophageal reflux disease (GERD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2015

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn; Sleep disorders
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Apr 2010 Results published in Alimentary Pharmacology and Therapeutics.
    • 04 Jun 2009 Results presented at Digestive Disease Week 2009.
    • 02 Jun 2009 Primary endpoint 'Resolution of night time heartburn' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top